Mutations associated with FDA‐approved therapies in other cancer types, which were potentially actionable, included three PIK3CA mutations (p.K111E, p.G118D, and p.E545K), two BRAF mutations (p.G466R and p.D594G, respectively), one ERBB2 p.H878Y mutation, a MAP2K1 p.P124S mutation, and an AKT1 mutation (p.E17K). This evidence concerns the gene BRAF and cancer.